SORAFENIB

作品数：318被引量：1563H指数：18
导出分析报告
相关领域：医药卫生更多>>
相关作者：曾普华郜文辉刘霞孙惠川汤钊猷更多>>
相关机构：湖南中医药大学福建医科大学中山大学复旦大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金中国博士后科学基金广东省自然科学基金国家重点基础研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Hepatobiliary Surgery and Nutritionx
共 条 记 录，以下是1-8
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Extended pancreatoduodenectomy with portal vein and inferior vena cava resection and reconstruction combined with sorafenib for hepatoid carcinoma of the pancreas:a strategy of superextended surgery combined with targeted therapy
《Hepatobiliary Surgery and Nutrition》2023年第4期637-640,I0027-I0030,共8页Deling Wei Banghao Xu Hai Zhu Jilong Wang Zongrui Jin Weitao Chen Jianyong Zhang Zhujing Lan Keyu Huang Ling Zhang Tingting Lu Ni Fang Ya Guo Tao Peng Minhao Peng Zhang Wen 
Hepatoid carcinoma of the pancreas(HCP)is an extremely rare pancreatic cancer resembling hepatocellular carcinoma,a type of liver cancer(1).Most reports have shown that it has an aggressive behavior and is associated ...
关键词：chemotherapy METASTASIS treatment 
Hepatocellular carcinoma as the Rose of Jericho:from the desert of sorafenib,to the blossoming of immunotherapy
《Hepatobiliary Surgery and Nutrition》2022年第3期485-488,共4页Antonio D’Alessio Lorenza Rimassa 
According to its etymology,the English word“liver”is related to the verb“to live”,and indeed there are few domains of oncology research as lively as liver cancer.The therapeutic landscape of hepatocellular carcino...
关键词：SORAFENIB IMMUNOTHERAPY MONOCLONAL 
Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma:a multi-center propensity score matched analysis of real-world practice被引量：3
《Hepatobiliary Surgery and Nutrition》2021年第5期631-645,I0009-I0016,共23页Shaohua Li Jie Mei Qiaoxuan Wang Feng Shi Hongyan Liu Ming Zhao Lianghe Lu Yihong Ling Zhixing Guo Yabing Guo Xiaoming Chen Ming Shi Wan Yee Lau Wei Wei Rongping Guo 
This study was supported by the National Natural Science Foundation of China(No.81871985);Natural Science Foundation of Guangdong Province(No.2018A0303130098 and No.2017A030310203);Science and Technology Planning Project of Guangdong Province(No.2017A020215112);Medical Scientific Research Foundation of Guangdong Province(No.A2017477);Science and Technology Planning Project of Guangzhou(No.201903010017 and No.201904010479);Clinical Trials Project(5010 Project)of Sun Yat-sen University(No.5010-2017009);and Clinical Trials Project(308 Project)of Sun Yat-sen University Cancer Center(No.308-2015-014).
Background:To compare the treatment effectiveness and safety among transarterial infusion chemotherapy(TAI)with FOLFOX regimen,transarterial chemoembolization(TACE),and sorafenib in patients with BCLC stage C hepatoce...
关键词：Hepatocellular carcinoma(HCC) transarterial infusion chemotherapy SORAFENIB transarterial chemoembolization FOLFOX 
Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians被引量：9
《Hepatobiliary Surgery and Nutrition》2021年第1期59-75,共17页Daniel Geh Derek M.Manas Helen L.Reeves 
Importance:Non-alcoholic fatty liver disease(NAFLD)is a rapidly growing cause of chronic liver disease and is becoming a leading cause of hepatocellular carcinoma(HCC)in many developed countries.This presents major ch...
关键词：Non-alcoholic fatty liver disease(NAFLD) hepatocellular carcinoma(HCC) liver transplantation HEPATECTOMY catheter ablation SORAFENIB population surveillance 
Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC?
《Hepatobiliary Surgery and Nutrition》2019年第5期546-548,共3页Yeo Jeong So Sophia Frentzas Eva Segelov 
Hepatocellular carcinoma(HCC)is the sixth most commonincident and the fourth most common cause of cancer deathworldwide.It is strongly associated with chronic HepatitisB and C infection and excess alcohol intake(1),ma...
关键词：PATIENTS INTAKE DEATH 
Sorafenib and metformin: to be, or not to be, that is the question被引量：1
《Hepatobiliary Surgery and Nutrition》2019年第4期411-413,共3页Giulia Orsi Andrea Casadei-Gardini 
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and ranks second among global causes of cancer-related death (1). The epidemiological and etiological landscape of the disease is facing remarka...
关键词：NAFLD TRANSLATE LIKELY 
The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future被引量：2
《Hepatobiliary Surgery and Nutrition》2018年第6期487-489,共3页Carlo Sposito Vincenzo Mazzaferro 
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally.Hepatocellular carcinoma(HCC)represents nearly 90%of primary liver cancers,and constitutes a major healt...
关键词：PATIENTS Liver treatment 
The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond?被引量：3
《Hepatobiliary Surgery and Nutrition》2018年第3期221-224,共4页Feihu Xie Shi Feng Lejia Sun Yilei Mao 
In the past decade, sorafenib has been the only approved molecular-targeted agent for unresectable hepatocellular carcinoma (uHCC) without any authentic challenges. There has been an urging need for alternatives or su...
关键词：HEPATOCELLULAR SORAFENIB DRUGS 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部